Invention Grant
- Patent Title: Orally-bioavailable nucleoside analogs
-
Application No.: US17842402Application Date: 2022-06-16
-
Publication No.: US11638715B2Publication Date: 2023-05-02
- Inventor: Christopher J. Burns , Glen Coburn , Guo-Hua Chu , Stephen M. Condon , Steven A. Boyd , Daniel C. Pevear
- Applicant: Venatorx Pharmaceuticals, Inc.
- Applicant Address: US PA Malvern
- Assignee: Venatorx Pharmaceuticals, Inc.
- Current Assignee: Venatorx Pharmaceuticals, Inc.
- Current Assignee Address: US PA Malvern
- Agency: Wilson Sonsini Goodrich & Rosati
- Main IPC: A61K31/7076
- IPC: A61K31/7076 ; A61K9/48 ; C07H19/16 ; C07H19/06 ; C07F9/6561 ; C07H19/10 ; A61K31/53 ; A61K31/7072 ; A61K31/685 ; A61K31/675 ; A61K9/00 ; A61K9/20 ; C07D487/04
Abstract:
Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 infection.
Public/Granted literature
- US20230024722A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS Public/Granted day:2023-01-26
Information query
IPC分类:
